P53 gene mutations: Case study of a clinical marker for solid tumors

Seminars in Oncology

Volumn 29, Issue 3, 2002, Pages 246-257

  Liu, Minetta C ^a   Gelmann, Edward P ^a  

^a GEORGETOWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BLADDER CANCER; BREAST CANCER; DIAGNOSTIC VALUE; DISEASE COURSE; GENE MUTATION; HEAD AND NECK CANCER; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG CANCER; NONHUMAN; OUTCOMES RESEARCH; PREDICTION; PRIORITY JOURNAL; PROSTATE CANCER; TUMOR SUPPRESSOR GENE;

EID: 0036272911     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/sonc.2002.32900     Document Type: Article

References (93)

1. Prognostic significance of progesterone receptor levels in estrogen receptor-positive patients with metastatic breast cancer treated with tamoxifen: Results of a prospective Southwest Oncology Group study
2. Role of progesterone receptors in breast cancer
3. c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer
4. Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas
5. p53, the cellular gatekeeper for growth and division
6. p53: Death star
7. MDM2 and CDK4 gene amplification in Ewing's sarcoma
8. Alternative product of the p16/CKDN 2A locus connects the Rb and p53 tumor suppressors
9. p16(MTS-1/CDKN2/INK4a) in cancer progression
10. Mutations in the p53 tumor suppressor gene: Clues to cancer etiology and molecular pathogenesis
11. A novel protein with strong homology to the tumor suppressor p53
12. Cloning and functional analysis of human p 51, which structurally and functionally resembles p53
13. Another p53 Doppelganger?
14. Mice deficient for p 53 are developmentally normal but susceptible to spontaneous tumours
15. p53 gene mutations occur in combination with 17p allelic deletions as late events in colorectal tumorigenesis
16. p53 in tumour pathology: Can we trust immunohistochemistry?-Revisited!
17. Activating mutations in p53 produce a common conformational effect. A monoclonal antibody specific for the mutant form
18. Apoptosis in cancer therapy: Crossing the threshold
19. An information-intensive approach to the molecular pharmacology of cancer
20. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents
21. p53 status and the efficacy of cancer therapy in vivo
22. Modulation of activity of the promoter of the human MDR 1 gene by Ras and p53
23. Inactivation of p53 enhances sensitivity to multiple chemotherapeutic agents
24. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas and other neoplasms
25. Mutated p53 gene is an independent adverse predictor of survival in colon carcinoma
26. Clinical response to fluorouracil and p53
27. Molecular predictors of survival after adjuvant chemotherapy for colon cancer
28. P53 alteration and microsatellite instability have predictive value for survival benefit from chemotherapy in stage III colorectal carcinoma
29. Long-term efficacy of intravesical bacillus Calmette-Guerin for carcinoma in situ: Relationship of progression to histological response and p53 nuclear accumulation
30. Overexpression of p53 protein in a high-risk population of patients with superficial bladder cancer before and after bacillus Calmette-Guerin therapy: Correlation to clinical outcome
31. Significance of p53 overexpression in urinary bladder transitional cell carcinoma in situ before and after bacillus Calmette-Guerin treatment
32. p53 expression compared with other prognostic factors in Oms grade-1 stage-Ta transitional cell carcinoma of the bladder
33. p53 nuclear overexpression and disease progression in Ta bladder carcinoma
34. Accumulation of nuclear p53 and tumor progression in bladder cancer
35. Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: A marker for disease progression
36. Prognostic value of p53 nuclear overexpression in patients with invasive bladder cancer treated with neoadjuvant MVAC
37. p53 and p53-regulated genes in bladder cancer
38. p53 and treatment of bladder cancer
39. Prognostic and predictive value of p53 and p21 in breast cancer
40. Overexpression of p53 in node-positive breast cancer
41. Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer
42. Prognostic significance of p53 gene alterations in node-negative breast cancer
43. Tumor microvessel density, p53 expression, tumor size, and peritumoral lymphatic vessel invasion are relevant prognostic markers in node-negative breast carcinoma
44. The p53 gene in breast cancer: Prognostic value of complementary DNA sequencing versus immunohistochemistry
45. Accumulation of p53 tumor suppressor gene protein: An independent marker of prognosis in breast cancers
46. p53 protein expression and oestrogen and progesterone receptor status in invasive ductal breast carcinomas
47. Prognostic factors in breast cancer: College of American Pathologists Consensus Statement 1999
48. Molecular biomarkers for breast cancer prognosis: Coexpression of cerbB-2 and p53
49. p53 in node-negative breast carcinoma: An immunohistochemical study of epidemiologic risk factors, histologic features, and prognosis
50. TP53 mutations in breast cancer associated with BRCA1 or BRCA2 germ-line mutations: Distinctive spectrum and structural distribution
51. The contribution of molecular markers to the prediction of response in the treatment of breast cancer: A review of the literature on HER-2, p53, and BCL- 2
52. Specific p53 mutations are associated with de novo reistance to doxorubicin in breast cancer patients
53. Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy
54. p53 mutations and overexpression in locally advanced breast cancers
55. p53 expression and the result of adjuvant therapy of breast cancer
56. Expression of drug resistance in breast cancer, in relation to chemotherapy
57. No significant predictive value of c-erb-B 2 or p53 expression regarding sensitivity to primary chemotherapy or radiotherapy in breast cancer
58. Accumulation of p53 protein as a possible predictor of response to adjuvant combination chemotherapy with cyclophosphamide, methotrexate, fluorouracil and prednisone for breast cancer
59. Clinical significance of p53 in non-small cell lung cancer
60. Tumor angiogenesis and biologic markers in resected stage I NSCLC
61. Immunocytochemical markers in stage I lung cancer: Relevance to prognosis
62. A prognostic model of recurrence and death in stage I non-small cell lung cancer utilizing presentation, histopathology, and oncoprotein expression
63. TP53 mutations in prostatic cancer. Analysis of pre- and post-treatment archival formalin-fixed tumour tissue
64. Correlation of genetic and immunodetection of TP 53 mutations in malignant and benign prostate tissues
65. p53 protein accumulation and gene mutation in the progression of human prostate carcinoma
66. Clustered p53 immunostaining: A novel pattern associated with prostate cancer progression
67. p53 nuclear protein expression is an independent prognostic marker in clinically localized prostate cancer patients undergoing radical prostatectomy
68. p53 status and prognosis of locally advanced prostatic adenocarcinoma: A study based on RTOG 8610
69. Small subgroup of aggressive, highly proliferative prostatic carcinomas defined by p53 accumulation
70. p53 expression and clinical outcome in prostate cancer
71. Proliferating cell nuclear antigen and p53 expression as prognostic factors in T1-2M0 prostatic adenocarcinoma
72. Immunohistochemical detection of p53 protein as a prognostic indicator in prostate cancer
73. Elevated levels of apoptosis regulator proteins p53 and bcl- 2 are independent prognostic biomarkers in surgically treated clinically localized prostate cancer
74. Protein expression of p53, bcl-2, and KI-67 (MIB-1) as prognostic biomarkers in patients with surgically treated, clinically localized prostate cancer
75. Combined analysis with Bcl-2 and P53 immunostaining predicts poorer prognosis in prostatic carcinoma
76. p53, bcl-2 and retinoblastoma proteins as long-term prognostic markers in localized carcinoma of the prostate
77. Assessment of the biologic markers p53, Ki-67, and apoptotic index as predictive indicators of prostate carcinoma recurrence after surgery
78. An evaluation of the markers p53 and Ki-67 for their predictive value in prostate cancer
79. Prognostic significance of Ki-67, p53, and Bcl-2 expression in prostate cancer patients with lymph node metastases: A retrospective immunohistochemical analysis
80. Expression of bcl-2 oncoprotein and p53 protein accumulation in bone marrow metastases of androgen independent prostate cancer
81. p53 alteration in regional lymph node metastases from prostate carcinoma: A marker for progression?
82. p53 gene status as a predictor of tumor response to induction chemotherapy of patients with locoregionally advanced squamous cell carcinomas of the head and neck
83. p53 alterations predict tumor response to neoadjuvant chemotherapy in head and neck squamous cell carcinoma: A prospective series
84. Molecular staging of head and neck squamous carcinoma
85. p53 gene mutation and protein accumulation during neoplastic progression in Barrett's esophagus
86. Diagnostic value of p53 immunohistochemistry in Barrett's esophagus: An endoscopic study
87. The incidence of p53 mutations increases with progression of head and neck cancer
88. Association between cigarette smoking and mutation of the p53 gene in squamous-cell carcinoma of the head and neck
89. Predicting cancer development in oral leukoplakia: Ten years of translational research
90. Pretreatment biomarkers predict response of advanced head and neck premalignant lesions to biochemoprevention
91. Identification of p53 gene mutations in bladder cancers and urine samples
92. Cancer: p53, guardian of the genome
93. Improving the detection of p53 mutations in breast cancer by use of the FASAY, a functional assay